TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
ABM Therapeutics Corporation
Sumitomo Pharma America, Inc.
Quadriga Biosciences, Inc.
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
Celgene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tocagen Inc.
Masonic Cancer Center, University of Minnesota
MedImmune LLC
Shenzhen Second People's Hospital
Memorial Sloan Kettering Cancer Center
University of Arizona
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
SWOG Cancer Research Network
National Cancer Institute (NCI)
Indiana University
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
Duke University
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Pharmacyclics LLC.
Thallion Pharmaceuticals